Abstract
Schizophrenia affects approximately 1% of the world population, and the majority of pharmacologically based treatments for this disorder are ligands that interact with monoaminergic transmission. However, there is a wealth of evidence that various neuropeptides are often co-released with monoamine neurotransmitters, and that ligands acting at neuropeptide receptors modulate monoaminergic transmission as well as schizophrenia-related behaviors in preclinical animal models. Such neuropeptide systems include neurotensin, cholecystokinin, corticotropin releasing factor, neuropeptide Y, oxytocin, opioid peptides, tachykinins, thyrotropin-releasing hormone, and orexins. The purpose of this review will be to summarize the existing preclinical and clinical literature on the role of various neuropeptide systems as modulators of schizophrenia-related behaviors, and the potential of targeting these systems for the development of novel antipsychotic medications.
Keywords: Schizophrenia, antipsychotic, dopamine, neuropeptide, positive symptoms, negative symptoms, cognitive deficits.
CNS & Neurological Disorders - Drug Targets
Title:Neuropeptide Systems and Schizophrenia
Volume: 12 Issue: 5
Author(s): Amber L. LaCrosse and M. Foster Olive
Affiliation:
Keywords: Schizophrenia, antipsychotic, dopamine, neuropeptide, positive symptoms, negative symptoms, cognitive deficits.
Abstract: Schizophrenia affects approximately 1% of the world population, and the majority of pharmacologically based treatments for this disorder are ligands that interact with monoaminergic transmission. However, there is a wealth of evidence that various neuropeptides are often co-released with monoamine neurotransmitters, and that ligands acting at neuropeptide receptors modulate monoaminergic transmission as well as schizophrenia-related behaviors in preclinical animal models. Such neuropeptide systems include neurotensin, cholecystokinin, corticotropin releasing factor, neuropeptide Y, oxytocin, opioid peptides, tachykinins, thyrotropin-releasing hormone, and orexins. The purpose of this review will be to summarize the existing preclinical and clinical literature on the role of various neuropeptide systems as modulators of schizophrenia-related behaviors, and the potential of targeting these systems for the development of novel antipsychotic medications.
Export Options
About this article
Cite this article as:
LaCrosse L. Amber and Olive Foster M., Neuropeptide Systems and Schizophrenia, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/1871527311312050010
DOI https://dx.doi.org/10.2174/1871527311312050010 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Main Receptors Involved in the COVID-19: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Recent Progress of Imaging Agents for Parkinson’s Disease
Current Neuropharmacology Cellular and Physiological Effects of Arginine
Mini-Reviews in Medicinal Chemistry Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology De novo Designed Lipopolysaccharide Binding Peptides: Structure Based Development of Antiendotoxic and Antimicrobial Drugs
Current Medicinal Chemistry A Study of the Relaxed Mechanisms Induced by Novokinin in the Isolated Porcine Coronary Artery Ring Segments
Protein & Peptide Letters α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Biosafety of Adenoviral Vectors
Current Gene Therapy TRP Channels: Emerging Links Between Ca2+, Kidney and Hypertension
Current Hypertension Reviews Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Crosslinked, Polymerized, and PEG-Conjugated Hemoglobin-Based Oxygen Carriers: Clinical Safety and Efficacy of Recent and Current Products
Current Drug Discovery Technologies General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design Current Understanding of Polymyxin B Applications in Bacteraemia/ Sepsis Therapy Prevention: Clinical, Pharmaceutical, Structural and Mechanistic Aspects
Anti-Infective Agents in Medicinal Chemistry Joshanda: A Traditional Herbal Approach for Treatment of Respiratory Catarrh
Current Respiratory Medicine Reviews New Trends in Thromboxane and Prostacyclin Modulators
Current Medicinal Chemistry Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology